General Information

Applications must be submitted via the online submission system. Applications submitted by email will not be accepted.
Submission deadline: Thursday 1 October 2026. Late submissions will not be considered.

Once submitted, applications cannot be edited. To make changes before the deadline, applicants must withdraw their submission and submit a new version. Withdrawals should be requested by email to eapci-scientific@escardio.org 

Applicants are responsible for ensuring that all information provided is complete and accurate at the time of submission.

Submitted technologies must not have been previously presented at another scientific congress or meeting. Applicants must disclose any previous presentation of the technology during the submission process.

1. Application Information

Technology Category

Please select the category that best describes your technology:

  • Coronary intervention devices and technologies
  • Structural heart technologies (valvular and non-valvular interventions)
  • Heart failure devices and technologies
  • Intravascular imaging & physiology (IVUS, OCT, FFR, iFR and related technologies)
  • Digital health, artificial intelligence & clinical decision support
  • Digital transformation and cath lab innovation
  • Robotics, navigation & automation
  • Simulation, training & education technologies
  • Smart technologies and wearable solutions for education, training and patient care
  • Emerging technologies

2. Clinical Application

Applicants should select the primary clinical area that best matches the intended clinical use of the technology.

3. Technology Development & Readiness

Development Stage

Technologies should be under clinical validation, market-ready or commercially available. 

Regulatory Status

Applicants should indicate whether the technology is:

  • CE marked
  • FDA cleared
  • NMPA cleared
  • Under regulatory review
  • Investigational
  • Not classified as a medical device

4. Application Content

Applicants will be asked to provide:

  • Technology name
  • Presenter's relationship to the technology (Inventor, Developer, Clinical User, Product Manager, Researcher or Other)
  • Funding and commercial support disclosures (mandatory)
  • Target users (Interventional Cardiologists, Cardiologists, Nurses & Allied Health Professionals, Patients, Researchers, other)
Technology Summary 

Applicants should address the following points:

  • Clinical need addressed
  • Technology overview
  • How the technology works
  • Current clinical evidence or validation
  • Current stage of implementation 
Innovation & Clinical Impact 

Applicants should explain:

  • What is novel about the technology?
  • What unmet need does it address?
  • What impact could it have on patient care or clinical practice?

Applicants may upload one PDF (maximum two pages) illustrating the technology or a representative clinical case. Patient information must be fully anonymised.

5. Presenter Information    

Applicants must provide:
Presenter Name
Email
Institution / Company
Country
Presenter Affiliation

  • Hospital / Healthcare Institution
  • University / Academic Institution
  • Research Institute
  • Commercial Organisation
  • Other 
Role in the Technology
  • Clinical Investigator
  • Clinical User
  • Inventor
  • Developer 
  • Researcher
  • Other 

Technologies may be submitted by any eligible applicant. If selected, the presentation must be delivered by an independent healthcare professional or researcher in accordance with CME accreditation requirements.
Submitted technology must report new information not presented at a national or international scientific meeting prior to the Congress. Note that technology previously presented at meetings will not be accepted unless there is a substantial update of data. 

6. Selection Process

Applications will undergo independent scientific review.
Selection will be based on:

  • Innovation / originality
  • Clinical relevance
  • Evidence supporting the technology
  • Potential impact on clinical practice

Preference may be given to technologies supported by clinical evidence, those addressing an important unmet clinical need, or those demonstrating a high potential to improve patient care or procedural practice.

Successful applicants will be notified in Early November.

Acceptance of a submission constitutes a commitment to register and present at the Congress in Milan.

7. Scientific Integrity

Submissions must present scientific or technical information and should not constitute commercial or promotional material.
All claims should be supported by appropriate evidence where available.
Patient confidentiality must be respected at all times.

8. Intellectual Property and Copyright

Applicants confirm that they are authorised to submit the technology and that the submission does not infringe any intellectual property or confidentiality rights.
Authors retain ownership of their intellectual property.
For accepted presentations, presenters grant the Organiser a non-exclusive licence to record, reproduce, publish and distribute the presentation for educational, scientific and promotional purposes in accordance with Congress policies.

9. Conflict of Interest

All presenters must disclose any relevant financial relationships, including employment, consultancy, advisory roles, research funding, stock ownership or intellectual property interests related to the submitted technology.
A disclosure slide must be shown at the beginning of the presentation.

10. Data Protection

By submitting an application, applicants confirm that all contributors have agreed to the processing of their personal data for the purposes of scientific review, programme development and Congress organisation.
Personal data will be processed in accordance with the General Data Protection Regulation (EU 2016/679).

11. Applicable Law

These Submission Rules are governed by French law.
The Organiser reserves the right to amend these rules in the event of exceptional circumstances or force majeure. Any updates will be published on the Congress website.